Positive News SentimentPositive News Catalyst Pharmaceuticals Stock Price, News & Analysis (NASDAQ:CPRX) $14.43 +0.38 (+2.70%) (As of 11/30/2023 ET) Add Compare Share Share Today's Range$14.06▼$14.5150-Day Range$11.69▼$14.4352-Week Range$11.09▼$22.11Volume1.18 million shsAverage Volume1.07 million shsMarket Capitalization$1.54 billionP/E Ratio27.75Dividend YieldN/APrice Target$24.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Catalyst Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside71.5% Upside$24.75 Price TargetShort InterestBearish7.27% of Float Sold ShortDividend StrengthN/ASustainability-1.99Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings Growth42.50%From $1.60 to $2.28 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.74 out of 5 starsMedical Sector70th out of 948 stocksPharmaceutical Preparations Industry23rd out of 448 stocks 3.5 Analyst's Opinion Consensus RatingCatalyst Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.75, Catalyst Pharmaceuticals has a forecasted upside of 71.5% from its current price of $14.43.Amount of Analyst CoverageCatalyst Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.27% of the float of Catalyst Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCatalyst Pharmaceuticals has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Catalyst Pharmaceuticals has recently increased by 3.74%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCatalyst Pharmaceuticals does not currently pay a dividend.Dividend GrowthCatalyst Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCatalyst Pharmaceuticals has received a 52.55% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Amifampridine" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Catalyst Pharmaceuticals is -1.99. Previous Next 3.3 News and Social Media Coverage News SentimentCatalyst Pharmaceuticals has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Catalyst Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 18 people have searched for CPRX on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.MarketBeat Follows12 people have added Catalyst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Catalyst Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders12.10% of the stock of Catalyst Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.27% of the stock of Catalyst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Catalyst Pharmaceuticals are expected to grow by 42.50% in the coming year, from $1.60 to $2.28 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Catalyst Pharmaceuticals is 27.75, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 113.11.Price to Earnings Ratio vs. SectorThe P/E ratio of Catalyst Pharmaceuticals is 27.75, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 101.63.Price to Book Value per Share RatioCatalyst Pharmaceuticals has a P/B Ratio of 4.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Catalyst Pharmaceuticals Stock (NASDAQ:CPRX)Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.Read More CPRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CPRX Stock News HeadlinesNovember 16, 2023 | finance.yahoo.comCatalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare ConferenceNovember 10, 2023 | finance.yahoo.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q3 2023 Earnings Call TranscriptDecember 1, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. November 8, 2023 | benzinga.comRecap: Catalyst Pharmaceuticals Q3 EarningsNovember 8, 2023 | finance.yahoo.comCatalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate UpdateNovember 5, 2023 | finance.yahoo.comCatalyst Pharmaceuticals Inc (CN2.DU)November 2, 2023 | finance.yahoo.comAmylyx Pharmaceuticals, Inc. (AMLX) Earnings Expected to Grow: What to Know Ahead of Q3 ReleaseNovember 2, 2023 | finance.yahoo.comCatalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®December 1, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. October 31, 2023 | seekingalpha.comCatalyst Pharmaceuticals: Agamree Approval Selloff A Long-Term Buying OpportunityOctober 30, 2023 | finance.yahoo.comInstitutional owners may take dramatic actions as Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) recent 4.2% drop adds to one-year lossesOctober 28, 2023 | finanznachrichten.deCatalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSEOctober 23, 2023 | finance.yahoo.comCatalyst Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 8, 2023October 20, 2023 | marketwatch.comCatalyst Pharmaceuticals Director to Succeed Retiring CEOOctober 19, 2023 | bizjournals.comPharmaceutical company names former AstraZeneca exec new CEO, founder to retireOctober 19, 2023 | finance.yahoo.comCatalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive OfficerOctober 16, 2023 | finance.yahoo.comPatrick J. McEnany, Chairman and CEO of Catalyst Pharmaceuticals, Receives Prestigious 2023 Lifetime Achievement Award from BioFloridaOctober 14, 2023 | finance.yahoo.comThose who invested in Catalyst Pharmaceuticals (NASDAQ:CPRX) three years ago are up 291%October 13, 2023 | markets.businessinsider.comCatalyst Pharma Reports FDA Acceptance Of SNDA For FIRDAPSEOctober 13, 2023 | finance.yahoo.comCatalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSE®September 27, 2023 | finance.yahoo.comIf EPS Growth Is Important To You, Catalyst Pharmaceuticals (NASDAQ:CPRX) Presents An OpportunitySeptember 21, 2023 | marketwatch.comCatalyst Pharmaceuticals Inc. stock falls Thursday, still outperforms marketSeptember 18, 2023 | finance.yahoo.comCatalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare ConferenceSeptember 9, 2023 | seekingalpha.comCatalyst Pharmaceuticals launches $500M mixed shelf offering - filingSeptember 8, 2023 | finance.yahoo.comWhy Is Catalyst (CPRX) Down 14% Since Last Earnings Report?September 8, 2023 | stocknews.comSeptember Buy, Sell or Hold for This Pharma Sock: Catalyst Pharmaceuticals (CPRX)September 6, 2023 | finance.yahoo.comUnraveling the Future of Catalyst Pharmaceuticals Inc (CPRX): A Deep Dive into Key MetricsSee More Headlines Receive CPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2023Today12/01/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/20/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CPRX CUSIPN/A CIK1369568 Webwww.catalystpharma.com Phone(305) 420-3200Fax305-529-0933Employees82Year Founded2002Price Target and Rating Average Stock Price Target$24.75 High Stock Price Target$27.00 Low Stock Price Target$24.00 Potential Upside/Downside+71.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$0.52 Trailing P/E Ratio27.75 Forward P/E Ratio9.02 P/E GrowthN/ANet Income$83.08 million Net Margins17.81% Pretax Margin23.20% Return on Equity19.32% Return on Assets16.00% Debt Debt-to-Equity RatioN/A Current Ratio3.32 Quick Ratio3.17 Sales & Book Value Annual Sales$214.20 million Price / Sales7.18 Cash Flow$0.83 per share Price / Cash Flow17.34 Book Value$3.27 per share Price / Book4.41Miscellaneous Outstanding Shares106,610,000Free Float93,711,000Market Cap$1.54 billion OptionableOptionable Beta1.08 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Patrick J. McEnany (Age 76)Co-Founder, Chairman, President & CEO Comp: $1.2MMs. Alicia Grande C.M.A. (Age 52)CPA, Chief Accounting Officer, VP, Treasurer & CFO Comp: $667.91kDr. Steven R. Miller Ph.D. (Age 61)COO & Chief Scientific Officer Comp: $809.03kDr. Gary Ingenito M.D. (Age 67)Ph.D., Chief Medical & Regulatory Officer Comp: $751.85kMr. Jeffrey Del Carmen (Age 52)Chief Commercial Officer Comp: $711.7kMs. Mary ColemanVP & Head of Investor RelationsMr. Brian Elsbernd J.D. (Age 59)Chief Compliance Officer & Chief Legal Officer Comp: $311.42kMr. Pete Curry Sr.Vice President of SalesDr. Stanley Iyadurai M.D.Ph.D., Senior Vice President of Medical Affairs & Drug DiscoveryDr. Preethi Sundaram Ph.D. (Age 47)Chief Strategy Officer Comp: $511.25kMore ExecutivesKey CompetitorsIronwood PharmaceuticalsNASDAQ:IRWDSupernus PharmaceuticalsNASDAQ:SUPNPOINT Biopharma GlobalNASDAQ:PNTMirum PharmaceuticalsNASDAQ:MIRMMerusNASDAQ:MRUSView All CompetitorsInsiders & InstitutionsAmerican Century Companies Inc.Bought 153,697 shares on 11/30/2023Ownership: 0.844%Deutsche Bank AGSold 854,991 shares on 11/24/2023Ownership: 0.100%Public Sector Pension Investment BoardSold 49,231 shares on 11/22/2023Ownership: 0.116%Graham Capital Management L.P.Bought 24,173 shares on 11/22/2023Ownership: 0.023%Walleye Capital LLCBought 8,650 shares on 11/21/2023Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions CPRX Stock Analysis - Frequently Asked Questions Should I buy or sell Catalyst Pharmaceuticals stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CPRX shares. View CPRX analyst ratings or view top-rated stocks. What is Catalyst Pharmaceuticals' stock price target for 2024? 4 analysts have issued 12-month price objectives for Catalyst Pharmaceuticals' stock. Their CPRX share price targets range from $24.00 to $27.00. On average, they anticipate the company's share price to reach $24.75 in the next twelve months. This suggests a possible upside of 71.5% from the stock's current price. View analysts price targets for CPRX or view top-rated stocks among Wall Street analysts. How have CPRX shares performed in 2023? Catalyst Pharmaceuticals' stock was trading at $18.60 at the start of the year. Since then, CPRX stock has decreased by 22.4% and is now trading at $14.43. View the best growth stocks for 2023 here. When is Catalyst Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024. View our CPRX earnings forecast. How were Catalyst Pharmaceuticals' earnings last quarter? Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) released its quarterly earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, meeting the consensus estimate of ($0.26). The biopharmaceutical company had revenue of $102.69 million for the quarter, compared to the consensus estimate of $100.17 million. Catalyst Pharmaceuticals had a net margin of 17.81% and a trailing twelve-month return on equity of 19.32%. What ETFs hold Catalyst Pharmaceuticals' stock? ETFs with the largest weight of Catalyst Pharmaceuticals (NASDAQ:CPRX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Invesco Biotechnology & Genome ETF (PBE), Janus Henderson Small Cap Growth Alpha ETF (JSML), SPDR S&P Biotech ETF (XBI), Invesco S&P SmallCap Health Care ETF (PSCH), ERShares NextGen Entrepreneurs ETF (ERSX), Invesco S&P SmallCap 600 Pure Growth ETF (RZG) and ALPS Medical Breakthroughs ETF (SBIO). What other stocks do shareholders of Catalyst Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD). Who are Catalyst Pharmaceuticals' major shareholders? Catalyst Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Northern Trust Corp (1.35%), Jacobs Levy Equity Management Inc. (1.23%), LSV Asset Management (1.16%), Invesco Ltd. (0.96%), Charles Schwab Investment Management Inc. (0.86%) and American Century Companies Inc. (0.84%). Insiders that own company stock include Alicia Grande, Brian Elsbernd, Carmen Jeffrey Del, David S Tierney, Donald A Denkhaus, Gary Ingenito, Patrick J Mcenany, Philip H Coelho, Preethi Sundaram and Steve Miller. View institutional ownership trends. How do I buy shares of Catalyst Pharmaceuticals? Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:CPRX) was last updated on 12/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.